Keratoconus Treatment Market: Information by Keratoconus Type (Corneal Hydrops, Forme Fruste Keratoconus, Posterior Keratoconus, Keratoglobus, Pellucid Marginal Degeneration), Treatment Type (Lenses, Surgery, Corneal Cross-Linking), End User (Eye Clinics, Hospitals), and Region(Americas, Europe, Asia-Pacific, and Middle East & Africa)—Forecast till 2027
ID: MRFR/HC/2574-CR | July 2021 | Region: Global | 153 pages
Keratoconus treatment Market Forecast:
The keratoconus treatment market was valued at USD 358.55 million in 2019 and is expected to register a CAGR of 4.72% during the forecast period of 2020 to 2027.
Market Overview:
Keratoconus is a progressive eye condition in which the cornea, usually round and small, appears cone-like. Keratoconus frequently has to do with light overexposure, constant eye rubbing, improperly fitting contact lenses, and chronic eye irritation. Keratoconus care depends on the seriousness of the disease and how easily the condition progresses.
The keratoconus treatment market is mainly driven by the increasing incidence of keratoconus disorders, increasing ultraviolet and sun exposure, and favorable government funding research and prevention programs of ophthalmic disorders. According to the American Journal of Ophthalmology, around 50-200 of every 100,000 people are afflicted with keratoconus. In addition, ultraviolet is regarded as one of the main causes for the development of keratoconus because of its oxidative damage. Thus, a higher prevalence of keratoconus has been identified in Saudi Arabia, Iran, New Zealand, Israel, and some Pacific Islands due to the high ultraviolet exposure.
COVID-19 Analysis:
COVID-19 has negatively impacted the global economy, shrinking it to up to 1% in 2020. As per the United Nations, the COVID-19 pandemic adversely affected the FDI flows. Manufacturing, local business, and investment have been badly affected by far-reaching social and economic repercussions. The COVID-19 crisis is primarily a public health threat.However, it is also a rising global threat. Itis a major cause of recession in some countries as well as a warning for a declining global annual growth rate to below 2.5%, which is often considered as the recessionary threshold for the world economy.Furthermore,the COVID-19 pandemic impacted the keratoconus treatment market and its financial capability. It also affected the ability of many companies to access capital, which severely impacted their short-term and long-term liquidity. For instance, the revenue of Bausch Health, best known for its contact lenses and branded generic drugs, had declined by more than 35% in 2020 due to COVID-19. The company estimated that a recession that persists through late Q3 or early Q4 2020 could reduce the company’s revenues by 15% from USD 8.6 billion in 2019 to USD 7.3 billion in 2020.
Market Dynamics:
Market Drivers
- Increasing incidence and prevalence of the keratoconus disorders
There has been an increase in cases with keratoconus disorder globally. The rising incidence and prevalence of keratoconus disorders also increase the demand for various treatment options such as lenses, surgeries, and corneal cross-linking. According to the American Journal of Ophthalmology, around 50-200 of every 100,000 people are afflicted with keratoconus. In the US, a study found a prevalence of 54.5 per 100,000 people. In addition, approximately 3 million people are affected by this disease worldwide. Thus, increasing keratoconus cases drive the use of different treatment methods such as intacs and corneal transplants, which drive the growth of this market.
- Increasing ultraviolet and sun exposure
- Favorable government funding
Market Restraints
- Lack of awareness
Many eye-related problems develop very slowly and are caused due to carelessness. Some of these problems are minor, while some need special treatments, which are expensive. In developing regions, a large number of people do not have enough capital to avail treatment for these diseases. Also, many of them have insufficient knowledge about such diseases, which increases the severity. As per the National Keratoconus Foundation, keratoconus occurs in about 1 out of every 2,000 people among the general population. It has been found that due to a lack of awareness and misdiagnosis, people become blind for a lifetime. It is reported that keratoconus is not considered a serious eye disease. Hence, there is less awareness among the public despite their noisome symptoms and complications. The lack of knowledge leading to the loss in timely management of keratoconus treatments is likely to hamper the market growth.
- Side-effects of keratoconus treatment
Market Opportunities
- Emerging markets of keratoconus treatment
Keratoconus has become a health problem across the globe that affects the quality of life. It is reported that generally, 50–200 of every 100,000 people are afflicted with keratoconus. In addition, keratoconus has greater disease progression in certain non-Asian ethnicities and Asians, particularly Indians, Pakistanis, Middle Easterners, and Polynesians, compared with the white population. Moreover, rising healthcare infrastructure in emerging countries further provides significant growth opportunities for the market. For instance, in Saudi Arabia, the number of keratoplasties performed for keratoconus patients has risen melodramatically. In 1983, keratoconus was the fourth-leading cause of keratoplasty, and 7.6% of keratoplasties surgeries were performed.By 2016, it was the leading cause of disease, and 48.2% of keratoplasties surgeries were performed. Thus, emerging markets of keratoconus treatment provide lucrative growth opportunities to the market players.
Keratoconus Treatment Market Share (%), by Keratoconus Type, 2019
Source: MRFR Analysis
Value Chain Analysis / Technology Analysis / Regulatory Implications
The value chain analysis for the keratoconus treatment industry comprises four major components, starting with the research & product development, followed by the manufacturing of the products, distribution, and ends with marketing & sales.The key market players focuson expanding the product portfolios through innovations in their current portfolio and acquisitions. For instance, in January 2019, SynergEyes (US)announced the launch of the SimplifEyes 1Day daily disposable lens.
Segment Overview
The keratoconus treatment market has been divided based on keratoconus type, treatment type, and end user.
By Keratoconus Type
- Corneal hydrops
Corneal hydrops is a type of advanced keratoconus characterized by the sudden inception of severe corneal opacification because of edema. The edema occurs from a spontaneous break in the Descemet's membrane because of the weakened cornea, leading to a painful low in visual acuity. Corneal hydrops management includes hypertonic sodium chloride to prevent epithelial edema and cycloplegia for comfort.
- Forme fruste keratoconus
Forme fruste keratoconus can be defined as a cornea with no abnormal findings byPlacido-based corneal topography and slit-lamp examinations and with the fellow eye of clinical keratoconus.
- Posterior keratoconus
Posterior keratoconus is a non-progressive corneal and rare. This type of disease is also known as keratoconus posticus. It is characterized by the thinning of the posterior cornea without ectasia of the anterior cornea. It represents corneal opacity and is generally considered a developmental abnormality.However, it can also be acquired after ocular trauma.
- Keratoglobus
Keratoglobus is a type of rare non-inflammatory corneal thinning disorder that is characterized by generalized thinning and globular ectasis (protrusion) of the cornea. The non-inflammatory corneal ectasias are a group of disorders characterized by corneal thinning, protrusion, and scarring.
- Pellucid marginal degeneration
Pellucid marginal corneal degeneration is a non-inflammatory bilateral corneal ectasia, most frequently include the inferior peripheral cornea in a crescentic pattern.
- Others
Others include nipple cone, oval cone, globus cone, and others. A nipple cone is a small, isolated area of bulging at the center of the cornea.
By Treatment Type
- Corneal Cross-linking
This procedure, also known as corneal collagen cross-linking or CXL, strengthens corneal tissue to halt bulging of the eye's surface in keratoconus. There are two versions of corneal cross-linking: epithelium-off and epithelium-on.
- Lenses
Patient vision depends on the severity of keratoconus. Mild to moderate keratoconus can be treated with contact lenses or eyeglasses. There are many types of lenses, such as custom soft contact lenses, gas permeable contact lenses, piggyback contact lenses, and hybrid contact lenses, which are used to treat keratoconus.
- Surgery
Surgery is performed in case of extreme thinning of the patient's cornea, corneal scarring, poor vision with the strongest prescription lenses, or an inability to wear any type of contact lenses. Depending on the location of the bulging cone and the severity of your condition, surgical options include penetrating keratoplasty and deep anterior lamellar keratoplasty (DALK).
- Other
Others include topography-guided photorefractive keratectomy (PRK), conductive keratoplasty, excimer laser, and superficial keratectomy (SK).
By End User
- Eye Clinics
Eye clinics are a prime place where most advanced eye procedures are conducted. The ophthalmologist suggests the right treatment consultation to the patients on the basis of the disease condition.
- Hospitals
A hospital is a health care institution providing patients specialized eye treatment with advanced medical equipment. Hospitals offer several types of surgical eye treatments, such as penetrating keratoplasty and deep anterior lamellar keratoplasty, and corneal collagen cross-linking. The availability of high proficient medical staff and advanced technological treatment facilities increase the patient flow in hospitals.
- Others
Others include academic institutes and medical research centers. These are providing advanced treatment options for keratoconus disorders.
Keratoconus TreatmentMarket Share (%), by Region, 2019
Source: MRFR Analysis
Regional Analysis:
The Keratoconus Treatment market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa.
Americas:
The Americas is likely to command the largest market share due to a well-developed healthcare sector, well-developed medical facilities, and ongoing technological advancements in the US. Additionally, a high number of cataract surgeries, mergers & acquisitions, and product launches in this region. As per the American Journal of Ophthalmology, around 50-200 of every 100,000 people are afflicted with keratoconus. In the US, a study found the prevalence of keratoconus in 54.5 per 100,000 people.
Europe:
Europe held a substantial share of the keratoconus treatment market. This can be attributed to the increasing support from the government, the well-developed medical industry in the region, and the growing cases of keratoconus. Availability of advanced diagnostic and therapeutic options is also playing an important role in the growth of this market.
Asia-Pacific:
Asia-Pacific is estimated to be the fastest-growing regional market due to the high merger and acquisition activities and product approvals in the region. For instance, In January 2018, Hoya Corporation opened an R&D center for cataract intraocular lenses in Singapore.
Middle East & Africa:
The keratoconus treatment market in Middle East & Africa is expected to witness steady growth during the review period. In the Middle East, the adoption rate of newer diagnostic instruments was high in South Africa, the UAE, and Saudi Arabia. With the increasing strategic initiatives by private and public firms and organizations, the growth rate is expected to rise in the next few years.
Competitive Landscape
The keratoconus treatment market is growing steadily due to the increasing incidences of keratoconus disorders. Increasing ultraviolet and sun exposure are also expected to drive the growth of the market. However, lack of awareness and side effects of keratoconus treatment are expected to hamper the growth of the market during the forecast period. Key players focus on merger and acquisition strategies that help them increase their revenue and product portfolio. For instance, in April 2018, Seed Co Limited acquired the optical manufacturer Contact Lens Precision Laboratories (CLPL), which owns UltraVision and Kerasoft brands. CLPL produces specialty and custom contact lenses and sells to more than 40 countries globally.
List of Key Companies Covered in this report:
- HOYA Vision Care Company (Japan) 2. Menicon Co., Ltd. (Japan) 3. Cooper Companies, Inc. (US) 4. Bausch Health (Canada) 5. SynergEyes (US) 6. Carl Zeiss Meditec AG (Germany) 7. Contamac (UK) 8. SEED Co., Ltd (Japan) 9. Novartis AG (Switzerland) 10. Johnson & Johnson Services, Inc. (US)
Recent Developments
- In December 2020, SynergEyes (US) announced the launch of the new, improved RxConnect Portal. The portal has been upgraded and updated to make the use of RxConnect easier than ever for SynergEyes customers.
- In April 2019, Novartis (Switzerland) announced the completion of the spin-off of its eyecare unit Alcon into a standalone entity after a strategic review concluded that spinning off the business would be consistent with Novartis' strategy of focusing as a medicines company.
- In September 2020, ZEISS Vision Care US, a subsidiary of Carl Zeiss Meditec AG (Germany), recently announced the launch of the ZEISS UVClean technology, an optometry-specific UV-C disinfecting device designed especially for eyecare professionals and developed in conjunction with Voxelight, LLC. ZEISS UVClean is now available for pre-ordering on a first-come-first-serve basis to eye care professionals in the US and Canada.
Report Overview:
The study covers the existing short-term and long-term market effects, helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The report analyzes market drivers, restraints, opportunities, challenges, Porter's five forces, value chain, and impact of COVID-19 on the market.
Scope of the Report & Segmentation
Keratoconus treatment Market, by Keratoconus Type
- Corneal Hydrops
- Forme Fruste Keratoconus Posterior Keratoconus
- Keratoglobus
- Pellucid Marginal Degeneration
- Others
Keratoconus treatment Market, by Treatment Type
- Corneal Cross-Linking
- Lenses
- Soft Contact Lenses
- Gas Permeable Contact Lenses
- Scleral and Semi-Scleral Lenses
- Piggybacking Contact Lenses
- Hybrid Contact Lenses
- Prosthetic Lenses
- Others
- Surgery
- Corneal Transplant
- Intacs
- Others
- Others
Keratoconus treatment Market, by End User
- Eye Clinics
- Hospitals
- Others
Keratoconus treatment Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- Europe
- Western Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | 2027: USD 358.55 million |
| CAGR | 4.72% |
| Base Year | 2019 |
| Forecast Period | 2020-2027 |
| Historical Data | 2017 & 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Keratoconus Type, Treatment Type, End User, and Region |
| Geographies Covered | Americas, Europe, Asia-Pacific, Middle East & Africa |
| Key Vendors | BioMérieux SA (France) Beckman Coulter, Inc. (US) Bio-Rad Laboratories, Inc. (US) F. Hoffmann-La Roche Ltd (Switzerland) Merck KGaA (Germany) Thermo Fisher Scientific Inc. (US) Qiagen (Germany) Shimadzu Corporation (Japan) Agilent Technologies Inc. (US) Bruker (US) |
| Key Market Opportunities | Emerging markets of keratoconus treatment |
| Key Market Drivers | • Increasing incidence and prevalence of the keratoconus disorder • Increasing ultraviolet and sun exposure • Favorable government funding |
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 14
1.1 OVERVIEW 14
2 MARKET INTRODUCTION 15
2.1 SCOPE OF THE STUDY 15
2.2 RESEARCH OBJECTIVE 15
2.3 LIST OF ASSUMPTIONS 16
3 RESEARCH METHODOLOGY 17
3.1 OVERVIEW 17
3.2 DATA MINING 17
3.3 SECONDARY RESEARCH 18
3.4 PRIMARY RESEARCH 19
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 19
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 20
3.5 FORECASTING TECHNIQUES 21
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22
3.6.1 BOTTOM-UP APPROACH 22
3.6.2 TOP-DOWN APPROACH 23
3.7 DATA TRIANGULATION 24
3.8 VALIDATION 24
4 MARKET DYNAMICS 25
4.1 INTRODUCTION 25
4.2 DRIVERS 26
4.2.1 INCREASING INCIDENCE AND PREVALENCE OF THE KERATOCONUS DISORDER 26
4.2.2 INCREASING ULTRAVIOLET AND SUN EXPOSURE 26
4.2.3 FAVORABLE GOVERNMENT FUNDING 27
4.3 RESTRAINTS 28
4.3.1 LACK OF AWARENESS 28
4.3.2 SIDE-EFFECTS OF KERATOCONUS TREATMENT 28
4.4 OPPORTUNITIES 29
4.4.1 EMERGING MARKETS OF KERATOCONUS TREATMENT 29
5 MARKET FACTOR ANALYSIS 30
5.1 VALUE CHAIN ANALYSIS 30
5.1.1 R&D AND DESIGNING 31
5.1.2 MANUFACTURING 31
5.1.3 DISTRIBUTION 31
5.1.4 MARKETING & SALES 31
5.2 PORTER’S FIVE FORCES MODEL 31
5.2.1 THREAT OF NEW ENTRANTS 32
5.2.2 BARGAINING POWER OF SUPPLIERS 32
5.2.3 THREAT OF SUBSTITUTES 33
5.2.4 BARGAINING POWER OF BUYERS 33
5.2.5 INTENSITY OF RIVALRY 33
5.3 COVID-19 IMPACT ANALYSIS 33
5.3.1 IMPACT ON MARKET GROWTH 33
5.3.2 IMPACT ON DEMAND AND SUPPLY 34
5.3.3 IMPACT ON MAJOR PLAYERS 34
6 GLOBAL KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TYPE 35
6.1 OVERVIEW 35
6.2 CORNEAL HYDROPS 36
6.3 FORME FRUSTE KERATOCONUS 36
6.4 POSTERIOR KERATOCONUS 37
6.5 KERATOGLOBUS 37
6.6 PELLUCID MARGINAL DEGENERATION 38
6.7 OTHERS 38
7 GLOBAL KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE 39
7.1 OVERVIEW 39
7.2 CORNEAL CROSS-LINKING 40
7.3 LENSES 40
7.4 SURGERY 42
7.5 OTHERS 43
8 GLOBAL KERATOCONUS TREATMENT MARKET, BY END USER 44
8.1 OVERVIEW 44
8.2 EYE CLINICS 45
8.3 HOSPITALS 45
8.4 OTHERS 46
9 GLOBAL KERATOCONUS TREATMENT MARKET, BY REGION 47
9.1 OVERVIEW 47
9.2 AMERICA 48
9.2.1 NORTH AMERICA 52
9.2.1.1 US 55
9.2.1.2 CANADA 57
9.2.2 LATIN AMERICA 59
9.3 EUROPE 61
9.3.1 WESTERN EUROPE 64
9.3.1.1 GERMANY 67
9.3.1.2 FRANCE 69
9.3.1.3 UK 71
9.3.1.4 ITALY 73
9.3.1.5 SPAIN 75
9.3.1.6 REST OF WESTERN EUROPE 77
9.3.2 EASTERN EUROPE 79
9.4 ASIA-PACIFIC 81
9.4.1 CHINA 84
9.4.2 INDIA 86
9.4.3 JAPAN 88
9.4.4 SOUTH KOREA 90
9.4.5 AUSTRALIA 92
9.4.6 REST OF ASIA-PACIFIC 94
9.5 MIDDLE EAST & AFRICA 96
9.5.1 MIDDLE EAST 99
9.5.2 AFRICA 101
10 COMPETITIVE LANDSCAPE 103
10.1 OVERVIEW 103
10.2 COMPETITIVE BENCHMARKING 104
10.3 GLOBAL KERATOCONUS TREATMENT MARKET: COMPANY RANKING, 2019 105
10.4 MAJOR GROWTH STRATEGY IN THE GLOBAL KERATOCONUS TREATMENT MARKET 106
10.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 106
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 107
10.6.1 PRODUCT APPROVALS AND LAUNCHES 107
10.6.2 ACQUISITIONS & SPIN OFF 108
10.7 FINANCIAL MATRIX 109
11 COMPANY PROFILES 110
11.1 BAUSCH HEALTH COMPANIES INC. 110
11.1.1 COMPANY OVERVIEW 110
11.1.2 FINANCIAL OVERVIEW 111
11.1.3 PRODUCTS/SERVICES OFFERED 112
11.1.4 KEY DEVELOPMENTS 112
11.1.5 SWOT ANALYSIS 113
11.1.6 KEY STRATEGIES 113
11.2 NOVARTIS AG 114
11.2.1 COMPANY OVERVIEW 114
11.2.2 FINANCIAL OVERVIEW 115
11.2.3 PRODUCTS/SERVICES OFFERED 115
11.2.4 KEY DEVELOPMENTS 116
11.2.5 SWOT ANALYSIS 116
11.2.6 KEY STRATEGIES 116
11.3 THE COOPER COMPANIES, INC. 117
11.3.1 COMPANY OVERVIEW 117
11.3.2 FINANCIAL OVERVIEW 117
11.3.3 PRODUCTS/SERVICES OFFERED 118
11.3.4 KEY DEVELOPMENTS 118
11.3.5 SWOT ANALYSIS 119
11.3.6 KEY STRATEGIES 119
11.4 HOYA CORPORATION 120
11.4.1 COMPANY OVERVIEW 120
11.4.2 FINANCIAL OVERVIEW 120
11.4.3 PRODUCTS/SERVICES OFFERED 121
11.4.4 KEY DEVELOPMENTS 121
11.4.5 SWOT ANALYSIS 122
11.4.6 KEY STRATEGIES 122
11.5 JOHNSON & JOHNSON SERVICES, INC. 123
11.5.1 COMPANY OVERVIEW 123
11.5.2 FINANCIAL OVERVIEW 124
11.5.3 PRODUCTS/SERVICES OFFERED 125
11.5.4 KEY DEVELOPMENTS 126
11.5.5 SWOT ANALYSIS 126
11.5.6 KEY STRATEGIES 126
11.6 CARL ZEISS MEDITEC AG 127
11.6.1 COMPANY OVERVIEW 127
11.6.2 FINANCIAL OVERVIEW 127
11.6.3 RODUCTS/SERVICES OFFERED 128
11.6.4 KEY DEVELOPMENTS 128
11.6.5 SWOT ANALYSIS 129
11.6.6 KEY STRATEGIES 129
11.7 CONTAMAC 130
11.7.1 COMPANY OVERVIEW 130
11.7.2 FINANCIAL OVERVIEW 130
11.7.3 PRODUCTS/SERVICES OFFERED 130
11.7.4 KEY DEVELOPMENTS 131
11.7.5 SWOT ANALYSIS 131
11.7.6 KEY STRATEGIES 131
11.8 SEED CO., LTD 132
11.8.1 COMPANY OVERVIEW 132
11.8.2 FINANCIAL OVERVIEW 132
11.8.3 PRODUCTS/SERVICES OFFERED 133
11.8.4 KEY DEVELOPMENTS 133
11.8.5 SWOT ANALYSIS 134
11.8.6 KEY STRATEGIES 134
11.9 SYNERGEYES 135
11.9.1 COMPANY OVERVIEW 135
11.9.2 FINANCIAL OVERVIEW 135
11.9.3 PRODUCTS/SERVICES OFFERED 135
11.9.4 KEY DEVELOPMENTS 136
11.9.5 SWOT ANALYSIS 136
11.9.6 KEY STRATEGIES 136
11.10 MENICON CO., LTD 137
11.10.1 COMPANY OVERVIEW 137
11.10.2 FINANCIAL OVERVIEW 137
11.10.3 PRODUCTS/SERVICES OFFERED 138
11.10.4 KEY DEVELOPMENTS 139
11.10.5 SWOT ANALYSIS 139
11.10.6 KEY STRATEGIES 139
12 APPENDIX 140
12.1 REFERENCES 140
12.2 RELATED REPORTS 140
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS& LIMITATIONS 16
TABLE 2 EPIDEMIOLOGY OF KERATOCONUS IN VARIOUS COUNTRIES AROUND THE WORLD, 2018 26
TABLE 3 GLOBAL: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TYPE, 2017–2027 (USD MILLION) 35
TABLE 4 GLOBAL: KERATOCONUS TREATMENT MARKET, FOR CORNEAL HYDROPS, BY REGION, 2017–2027 (USD MILLION) 36
TABLE 5 GLOBAL: KERATOCONUS TREATMENT MARKET, FOR FORME FRUSTE KERATOCONUS, BY REGION, 2017–2027 (USD MILLION) 36
TABLE 6 GLOBAL: KERATOCONUS TREATMENT MARKET, FOR POSTERIOR KERATOCONUS, BY REGION, 2017–2027 (USD MILLION) 37
TABLE 7 GLOBAL: KERATOCONUS TREATMENT MARKET, FOR KERATOGLOBUS, BY REGION, 2017–2027 (USD MILLION) 37
TABLE 8 GLOBAL: KERATOCONUS TREATMENT MARKET, FOR PELLUCID MARGINAL DEGENERATION, BY REGION, 2017–2027
(USD MILLION) 38
TABLE 9 GLOBAL: KERATOCONUS TREATMENT MARKET, BY TREAMENT TYPE, 2017–2027 (USD MILLION) 39
TABLE 10 GLOBAL: KERATOCONUS TREATMENT MARKET, FOR CORNEAL CROSS-LINKING, BY REGION, 2017–2027 (USD MILLION) 40
TABLE 11 GLOBAL: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY REGION, 2017–2027 (USD MILLION) 41
TABLE 12 GLOBAL: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE, 2017–2027 (USD MILLION) 41
TABLE 13 GLOBAL: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY REGION, 2017–2027 (USD MILLION) 42
TABLE 14 GLOBAL: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE, 2017–2027 (USD MILLION) 43
TABLE 15 GLOBAL: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 44
TABLE 16 GLOBAL: KERATOCONUS TREATMENT MARKET, FOR EYE CLINICS, BY REGION, 2017–2027 (USD MILLION) 45
TABLE 17 GLOBAL: KERATOCONUS TREATMENT MARKET, FOR HSOPITALS, BY REGION, 2017–2027 (USD MILLION) 46
TABLE 18 GLOBAL: KERATOCONUS TREATMENT MARKET, BY REGION, 2017–2027 (USD MILLION) 48
TABLE 19 AMERICA: KERATOCONUS TREATMENT MARKET, BY REGION, 2017–2027 (USD MILLION) 49
TABLE 20 AMERICA: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TYPE, 2017–2027 (USD MILLION) 50
TABLE 21 AMERICA: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 50
TABLE 22 AMERICA: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE,2017–2027 (USD MILLION) 51
TABLE 23 AMERICA: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE,2017–2027 (USD MILLION) 51
TABLE 24 AMERICA: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 51
TABLE 25 NORTH AMERICA: KERATOCONUS TREATMENT MARKET, BY COUNTRY, 2017–2027 (USD MILLION) 52
TABLE 26 NORTH AMERICA: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TREATMENT TYPE, 2017–2027 (USD MILLION) 53
TABLE 27 NORTH AMERICA: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 53
TABLE 28 NORTH AMERICA: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE, 2017–2027 (USD MILLION) 54
TABLE 29 NORTH AMERICA: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE, 2017–2027 (USD MILLION) 54
TABLE 30 NORTH AMERICA: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 54
TABLE 31 US: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TREATMENT TYPE, 2017–2027 (USD MILLION) 55
TABLE 32 US: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 55
TABLE 33 US: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE, 2017–2027 (USD MILLION) 56
TABLE 34 US: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE, 2017–2027 (USD MILLION) 56
TABLE 35 US: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 56
TABLE 36 CANADA: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TREATMENT TYPE, 2017–2027 (USD MILLION) 57
TABLE 37 CANADA: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 57
TABLE 38 CANADA: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE, 2017–2027 (USD MILLION) 58
TABLE 39 CANADA: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE, 2017–2027 (USD MILLION) 58
TABLE 40 CANADA: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 58
TABLE 41 LATIN AMERICA: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TREATMENT TYPE, 2017–2027 (USD MILLION) 59
TABLE 42 LATIN AMERICA: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 59
TABLE 43 LATIN AMERICA: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE, 2017–2027 (USD MILLION) 60
TABLE 44 LATIN AMERICA: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE, 2017–2027 (USD MILLION) 60
TABLE 45 LATIN AMERICA: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 60
TABLE 46 EUROPE: KERATOCONUS TREATMENT MARKET, BY REGION, 2017–2027 (USD MILLION) 61
TABLE 47 EUROPE: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TYPE, 2017–2027 (USD MILLION) 62
TABLE 48 EUROPE: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 62
TABLE 49 EUROPE: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE,2017–2027 (USD MILLION) 63
TABLE 50 EUROPE: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE,2017–2027 (USD MILLION) 63
TABLE 51 EUROPE: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 63
TABLE 52 WESTERN EUROPE: KERATOCONUS TREATMENT MARKET, BY COUNTRY, 2017–2027 (USD MILLION) 64
TABLE 53 WESTERN EUROPE: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TREATMENT TYPE, 2017–2027 (USD MILLION) 65
TABLE 54 WESTERN EUROPE: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 65
TABLE 55 WESTERN EUROPE: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE, 2017–2027 (USD MILLION) 66
TABLE 56 WESTERN EUROPE: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE, 2017–2027 (USD MILLION) 66
TABLE 57 WESTERN EUROPE: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 66
TABLE 58 GERMANY: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TREATMENT TYPE, 2017–2027 (USD MILLION) 67
TABLE 59 GERMANY: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 67
TABLE 60 GERMANY: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE, 2017–2027 (USD MILLION) 68
TABLE 61 GERMANY: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE, 2017–2027 (USD MILLION) 68
TABLE 62 GERMANY: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 68
TABLE 63 FRANCE: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TREATMENT TYPE, 2017–2027 (USD MILLION) 69
TABLE 64 FRANCE: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 69
TABLE 65 FRANCE: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE, 2017–2027 (USD MILLION) 70
TABLE 66 FRANCE: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE, 2017–2027 (USD MILLION) 70
TABLE 67 FRANCE: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 70
TABLE 68 UK: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TREATMENT TYPE, 2017–2027 (USD MILLION) 71
TABLE 69 UK: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 71
TABLE 70 UK: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE, 2017–2027 (USD MILLION) 72
TABLE 71 UK: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE, 2017–2027 (USD MILLION) 72
TABLE 72 UK: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 72
TABLE 73 ITALY: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TREATMENT TYPE, 2017–2027 (USD MILLION) 73
TABLE 74 ITALY: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 73
TABLE 75 ITALY: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE, 2017–2027 (USD MILLION) 74
TABLE 76 ITALY: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE, 2017–2027 (USD MILLION) 74
TABLE 77 ITALY: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 74
TABLE 78 SPAIN: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TREATMENT TYPE, 2017–2027 (USD MILLION) 75
TABLE 79 SPAIN: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 75
TABLE 80 SPAIN: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE, 2017–2027 (USD MILLION) 76
TABLE 81 SPAIN: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE, 2017–2027 (USD MILLION) 76
TABLE 82 SPAIN: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 76
TABLE 83 REST OF WESTERN EUROPE: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TREATMENT TYPE, 2017–2027 (USD MILLION) 77
TABLE 84 REST OF WESTERN EUROPE: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 77
TABLE 85 REST OF WESTERN EUROPE: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE, 2017–2027 (USD MILLION) 78
TABLE 86 REST OF WESTERN EUROPE: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE, 2017–2027 (USD MILLION) 78
TABLE 87 REST OF WESTERN EUROPE: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 78
TABLE 88 EASTERN EUROPE: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TREATMENT TYPE, 2017–2027 (USD MILLION) 79
TABLE 89 EASTERN EUROPE: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 79
TABLE 90 EASTERN EUROPE: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE, 2017–2027 (USD MILLION) 80
TABLE 91 EASTERN EUROPE: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE, 2017–2027 (USD MILLION) 80
TABLE 92 EASTERN EUROPE: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 80
TABLE 93 ASIA-PACIFIC KERATOCONUS TREATMENT MARKET, BY COUNTRY, 2017–2027 (USD MILLION) 81
TABLE 94 ASIA-PACIFIC: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TYPE, 2017–2027 (USD MILLION) 82
TABLE 95 ASIA-PACIFIC: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 82
TABLE 96 ASIA-PACIFIC: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE,2017–2027 (USD MILLION) 83
TABLE 97 ASIA-PACIFIC: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE,2017–2027 (USD MILLION) 83
TABLE 98 ASIA-PACIFIC: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 83
TABLE 99 CHINA: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TREATMENT TYPE, 2017–2027 (USD MILLION) 84
TABLE 100 CHINA: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 84
TABLE 101 CHINA: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE, 2017–2027 (USD MILLION) 85
TABLE 102 CHINA: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE, 2017–2027 (USD MILLION) 85
TABLE 103 CHINA: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 85
TABLE 104 INDIA: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TREATMENT TYPE, 2017–2027 (USD MILLION) 86
TABLE 105 INDIA: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 86
TABLE 106 INDIA: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE, 2017–2027 (USD MILLION) 87
TABLE 107 INDIA: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE, 2017–2027 (USD MILLION) 87
TABLE 108 INDIA: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 87
TABLE 109 JAPAN: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TREATMENT TYPE, 2017–2027 (USD MILLION) 88
TABLE 110 JAPAN: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 88
TABLE 111 JAPAN: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE, 2017–2027 (USD MILLION) 89
TABLE 112 JAPAN: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE, 2017–2027 (USD MILLION) 89
TABLE 113 JAPAN: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 89
TABLE 114 SOUTH KOREA: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TREATMENT TYPE, 2017–2027 (USD MILLION) 90
TABLE 115 SOUTH KOREA: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 90
TABLE 116 SOUTH KOREA: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE, 2017–2027 (USD MILLION) 91
TABLE 117 SOUTH KOREA: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE, 2017–2027 (USD MILLION) 91
TABLE 118 SOUTH KOREA: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 91
TABLE 119 AUSTRALIA: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TREATMENT TYPE, 2017–2027 (USD MILLION) 92
TABLE 120 AUSTRALIA: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 92
TABLE 121 AUSTRALIA: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE, 2017–2027 (USD MILLION) 93
TABLE 122 AUSTRALIA: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE, 2017–2027 (USD MILLION) 93
TABLE 123 AUSTRALIA: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 93
TABLE 124 REST OF ASIA-PACIFIC: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TREATMENT TYPE, 2017–2027 (USD MILLION) 94
TABLE 125 REST OF ASIA-PACIFIC: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 94
TABLE 126 REST OF ASIA-PACIFIC: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE, 2017–2027 (USD MILLION) 95
TABLE 127 REST OF ASIA-PACIFIC: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE, 2017–2027 (USD MILLION) 95
TABLE 128 REST OF ASIA-PACIFIC: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 95
TABLE 129 MIDDLE EAST & AFRICA: KERATOCONUS TREATMENT MARKET, BY REGION, 2017–2027 (USD MILLION) 96
TABLE 130 MIDDLE EAST & AFRICA: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TYPE, 2017–2027 (USD MILLION) 97
TABLE 131 MIDDLE EAST & AFRICA: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 97
TABLE 132 MIDDLE EAST & AFRICA: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE,2017–2027 (USD MILLION) 98
TABLE 133 MIDDLE EAST & AFRICA: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE,2017–2027 (USD MILLION) 98
TABLE 134 MIDDLE EAST & AFRICA: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 98
TABLE 135 MIDDLE EAST: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TYPE, 2017–2027 (USD MILLION) 99
TABLE 136 MIDDLE EAST: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 99
TABLE 137 MIDDLE EAST: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE,2017–2027 (USD MILLION) 100
TABLE 138 MIDDLE EAST: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE,2017–2027 (USD MILLION) 100
TABLE 139 MIDDLE EAST: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 100
TABLE 140 AFRICA: KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TYPE, 2017–2027 (USD MILLION) 101
TABLE 141 AFRICA: KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 101
TABLE 142 AFRICA: KERATOCONUS TREATMENT MARKET, FOR LENSES, BY TYPE,2017–2027 (USD MILLION) 102
TABLE 143 AFRICA: KERATOCONUS TREATMENT MARKET, FOR SURGERY, BY TYPE,2017–2027 (USD MILLION) 102
TABLE 144 AFRICA: KERATOCONUS TREATMENT MARKET, BY END USER, 2017–2027 (USD MILLION) 102
TABLE 145 MAJOR MANUFACTURERS RANKING, 2019 105
TABLE 146 TOP PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL KERATOCONUS TREATMENT MARKET 106
TABLE 147 PRODUCT APPROVALS AND LAUNCHES 107
TABLE 148 ACQUISITIONS & SPIN OFF 108
TABLE 149 BAUSCH HEALTH COMPANIES INC.: PRODUCTS/SERVICES OFFERED 112
TABLE 150 BAUSCH HEALTH COMPANIES INC.: KEY DEVELOPMENTS 112
TABLE 151 NOVARTIS AG: PRODUCTS/SERVICES OFFERED 115
TABLE 152 BAUSCH HEALTH COMPANIES INC.: KEY DEVELOPMENTS 116
TABLE 153 THE COOPER COMPANIES, INC.: PRODUCTS/SERVICES OFFERED 118
TABLE 154 THE COOPER COMPANIES, INC.: KEY DEVELOPMENTS 118
TABLE 155 HOYA CORPORATION: PRODUCTS/SERVICES OFFERED 121
TABLE 156 HOYA CORPORATION: KEY DEVELOPMENTS 121
TABLE 157 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS/SERVICES OFFERED 125
TABLE 158 JOHNSON & JOHNSON SERVICES, INC: KEY DEVELOPMENTS 126
TABLE 159 CARL ZEISS MEDITEC AG: PRODUCTS/SERVICES OFFERED 128
TABLE 160 CARL ZEISS MEDITEC AG: KEY DEVELOPMENTS 128
TABLE 161 CONTAMAC: PRODUCTS/SERVICES OFFERED 130
TABLE 162 SEED CO., LTD: PRODUCTS/SERVICES OFFERED 133
TABLE 163 SEED CO., LTD: KEY DEVELOPMENTS 133
TABLE 164 SYNERGEYES: PRODUCTS/SERVICES OFFERED 135
TABLE 165 SYNERGEYES: KEY DEVELOPMENTS 136
TABLE 166 MENICON CO., LTD: PRODUCTS/SERVICES OFFERED 138
TABLE 167 MENICON CO., LTD: KEY DEVELOPMENTS 139
LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS 14
FIGURE 2 GLOBAL KERATOCONUS TREATMENT MARKET STRUCTURE 16
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 22
FIGURE 4 MARKET DYNAMICS OVERVIEW: KERATOCONUS TREATMENT MARKET 25
FIGURE 5 DRIVERS IMPACT ANALYSIS: KERATOCONUS TREATMENT MARKET 27
FIGURE 6 RESTRAINTS IMPACT ANALYSIS: KERATOCONUS TREATMENT MARKET 28
FIGURE 7 VALUE CHAIN: GLOBAL KERATOCONUS TREATMENT MARKET 30
FIGURE 8 PORTER’S FIVE FORCES ANALYSIS: GLOBAL KERATOCONUS TREATMENT MARKET 32
FIGURE 9 GLOBAL KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TYPES, 2019 & 2027 (USD MILLION) 35
FIGURE 10 GLOBAL: KERATOCONUS TREATMENT MARKET, TREATMENT TYPE, 2019 & 2027 (USD MILLION) 39
FIGURE 11 GLOBAL KERATOCONUS TREATMENT MARKET, END USER, 2019 & 2027 (USD MILLION) 44
FIGURE 12 GLOBAL KERATOCONUS TREATMENT MARKET, BY REGION 2019 & 2027 (USD MILLION) 47
FIGURE 13 AMERICA: KERATOCONUS TREATMENT MARKET SHARE, BY REGION, 2019 (%) 49
FIGURE 14 NORTH AMERICA: KERATOCONUS TREATMENT MARKET SHARE, BY COUNTRY 2019 (%) 52
FIGURE 15 EUROPE: KERATOCONUS TREATMENT MARKET SHARE, BY REGION, 2019 (%) 61
FIGURE 16 WESTERN EUROPE: KERATOCONUS TREATMENT MARKET SHARE, BY COUNTRY 2019 (%) 64
FIGURE 17 ASIA-PACIFIC: KERATOCONUS TREATMENT MARKET SHARE, BY COUNTRY 2019 (%) 81
FIGURE 18 MIDDLE EAST & AFRICA: KERATOCONUS TREATMENT MARKET SHARE, BY REGION 2019 (%) 96
FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS 104
FIGURE 20 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN GLOBAL KERATOCONUS TREATMENT MARKET 106
FIGURE 21 SALES & OPERATING INCOME MARGIN, 2019 109
FIGURE 22 RESEARCH & DEVELOPMENT EXPENDITURE, 2019 109
FIGURE 23 BAUSCH HEALTH COMPANIES INC.: FINANCIAL OVERVIEW SNAPSHOT 111
FIGURE 24 BAUSCH HEALTH COMPANIES INC.: SWOT ANALYSIS 113
FIGURE 25 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 115
FIGURE 26 NOVARTIS AG: SWOT ANALYSIS 116
FIGURE 27 THE COOPER COMPANIES, INC.: FINANCIAL OVERVIEW SNAPSHOT 117
FIGURE 28 THE COOPER COMPANIES, INC.: SWOT ANALYSIS 119
FIGURE 29 HOYA CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 120
FIGURE 30 HOYA CORPORATION: SWOT ANALYSIS 122
FIGURE 31 JOHNSON & JOHNSON SERVICES, INC.: FINANCIAL OVERVIEW SNAPSHOT 124
FIGURE 32 JOHNSON & JOHNSON SERVICES, INC.: SWOT ANALYSIS 126
FIGURE 33 CARL ZEISS MEDITEC AG: FINANCIAL OVERVIEW SNAPSHOT 127
FIGURE 34 CARL ZEISS MEDITEC AG: SWOT ANALYSIS 129
FIGURE 35 CONTAMAC: SWOT ANALYSIS 131
FIGURE 36 SEED CO., LTD: FINANCIAL OVERVIEW SNAPSHOT 132
FIGURE 37 SEED CO., LTD: SWOT ANALYSIS 134
FIGURE 38 SYNERGEYES: SWOT ANALYSIS 136
FIGURE 39 MENICON CO., LTD: FINANCIAL OVERVIEW SNAPSHOT 137
FIGURE 40 MENICON CO., LTD: SWOT ANALYSIS 139
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.